Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways
Anticancer Research · 2023
DOI: 10.21873/anticanres.16586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Li-Cho Hsu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Yang-Ming Chiao-Tung University Hospital, Yilan, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Oral squamous cell carcinoma (OSCC) has limited treatment options. This study investigated imipramine, a tricyclic antidepressant, as a potential therapy for OSCC using a SAS-bearing xenograft animal model. MATERIALS AND METHODS: The SAS-bearing xenograft model evaluated imipramine's impact on tumor growth. The control group received no treatment, while the imipramine-treated group received regular doses. Tumor growth, confirmed by imaging, and histological analysis assessed size and weight. Imipramine's effects on apoptosis, epithelial-to-mesenchymal transition (EMT), and transcription factors (AKT, ERK, STAT3) were analyzed. RESULTS: Imipramine significantly suppressed tumor growth within 6 days of treatment, with sustained activity. Computer tomography (CT) scans and histology confirmed reduced size and weight by imipramine. Imipramine induced apoptosis via caspase-dependent/-independent pathways, inhibited EMT, and down-regulated phosphorylated AKT, ERK, and STAT3. CONCLUSION: Imipramine shows promise as an effective OSCC therapy, inhibiting tumor growth, inducing apoptosis, and inhibiting EMT. Its impact on transcription factors and modulation of the AKT/ERK/STAT3 pathway suggest a multifaceted approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, National Yang-Ming Chiao-Tung University Hospital, Yilan, Taiwan, R.O.C.
- Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.
- Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
- Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
- Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; jackada093@yahoo.com.tw.
Zitieren
APA
Hsu, L. C., Lin, C. N., Hsu, F. T., Chen, Y. T., Chang, P. L., Hsieh, L. L., Wang, H. Y., Lin, K. H., Hsiao, H. C., & Tu, H. F. (2023). Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways. Anticancer Research. https://doi.org/10.21873/anticanres.16586
Vancouver
Hsu LC, Lin CN, Hsu FT, Chen YT, Chang PL, Hsieh LL, et al. Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways. Anticancer Research. 2023. doi:10.21873/anticanres.16586
BibTeX
@article{Hsu2023,
author = {Hsu, Li-Cho and Lin, Ching Ni and Hsu, Fei-Ting and Chen, Ying-Tzu and Chang, Po-Lung and Hsieh, Ling-Ling and Wang, Hsiao-Yu and Lin, Kuang-Hsuan and Hsiao, Hsin-Chang and Tu, Hsi-Feng},
title = {Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16586}
}
EUVIMED